Ubiquitin modification targets a protein for rapid degradation by the proteasome. However, polyubiquitination of proteins can result in multiple functions depending on the topology of the ubiquitin chain. Therefore, ubiquitin signaling offers a more complex and versatile biology compared with many other posttranslational modifications. One area of potential for the application of this knowledge is the field of ischemiainduced brain damage, as occurs following a stroke. The ubiquitin proteasome system may exert a dual role on neuronal outcome following ischemia. Harmful ischemia results in an overload of the ubiquitin proteasome system, and blocking the proteasome reduces brain infarction following ischemia. However, the rapid and selective degradation of proteins following brief ischemia results in endogenous protection against ischemia. Therefore, further understanding of the molecular signaling mechanisms that regulate the ubiquitin proteasome system may reveal novel therapeutic targets to reduce brain damage when ischemia is predicted or reduce the activation of the cell death mechanisms and the inflammatory response following stroke. The aim of this review is to discuss some of the recent advances in the understanding of protein ubiquitination and its implications for novel stroke therapies.
Ubiquitin modification targets a protein for rapid degradation by the proteasome. However, polyubiquitination of proteins can result in multiple functions depending on the topology of the ubiquitin chain. Therefore, ubiquitin signaling offers a more complex and versatile biology compared with many other posttranslational modifications. One area of potential for the application of this knowledge is the field of ischemiainduced brain damage, as occurs following a stroke. The ubiquitin proteasome system may exert a dual role on neuronal outcome following ischemia. Harmful ischemia results in an overload of the ubiquitin proteasome system, and blocking the proteasome reduces brain infarction following ischemia. However, the rapid and selective degradation of proteins following brief ischemia results in endogenous protection against ischemia. Therefore, further understanding of the molecular signaling mechanisms that regulate the ubiquitin proteasome system may reveal novel therapeutic targets to reduce brain damage when ischemia is predicted or reduce the activation of the cell death mechanisms and the inflammatory response following stroke. The aim of this review is to discuss some of the recent advances in the understanding of protein ubiquitination and its implications for novel stroke therapies.
Keywords: rapid ischemic tolerance; preconditioning; bcl-2; synapse; neuroprotection U biquitin was discovered in the 1970s as a small (9-kDa) covalent posttranslational modification of proteins. a role for ubiquitination in the proteasomal degradation of short-lived proteins was soon established (Ciechanover and others 1984; Finley and others 1984) . The discovery of the role of the ubiquitin proteasome system in the anaphase-promoting complex (aPC) regulation of the cell cycle awakened many scientists to the potential for this system to regulate many biological processes (Pickart 2004) . although ubiquitin is best known as a prelude to proteasomal protein degradation, it also regulates protein-protein interactions and therefore numerous biological processes, including protein translocation, signal transduction, gene transcription, apoptosis, and autophagic processes (Mukhopadhyay and Riezman 2007) .
What makes ubiquitin particularly versatile as a posttranslational modification is the variety of modifications that it can form. Ubiquitin is conjugated to a lysine residue on the substrate protein (although N terminal linkage has also been reported). The availability of seven lysine residues within the ubiquitin protein sequence enables the formation of polyubiquitin chains, each of which appears to encode different biological functions (Fig. 1) . The most common linkage is the Lys48 linkage, which is associated with protein degradation by the proteasome. In contrast, Lys63 linkages appear to play a role in protein-protein interactions mediating signal transduction, translocation, and DNa repair (although see below). Ubiquitin also regulates lysosomal as well as proteasomal protein degradation. Lys63-linked polyubiquitin modified proteins are targeted to the lysosome for processing (Ikeda and Kerppola 2008) . The role of other polyubiquitin lysine linkages is not yet clear and still subject to investigation (Ikeda and Dikic 2008) . With so many functions available to different polyubiquitin additions, it is clear that the process of polyubiquitination must be tightly regulated at a number of points.
Ubiquitin is added and removed from a target protein by e3-ligase and deubiquitinating enzymes, respectively, which function similarly to protein kinases and phosphatases regulating protein phosphorylation. The number of potential e3-ligases encoded in the genome is similar to the potential number of protein kinases, suggesting that ubiquitination may play a critical role in regulating as many biological processes as protein phosphorylation. The ubiquitin system requires a sequential process of e1-, e2-and e3-ligases to conjugate ubiquitin to a substrate (Hershko 1983; Fig. 1 ). Ubiquitin is synthesized as a precursor, and the C-terminus tail of the pro-protein is removed by a deubiquitinylating enzyme (DUB) to expose a C-terminal glycine residue (Lund and others 1985) . Ubiquitin forms a high-energy thioester bond with an e1-ligase, in a reaction requiring aTP (Pickart 2001) . This is the only step of the conjugation process that requires aTP and may account for the observation that ubiquitination may occur under conditions of low aTP levels such as ischemia (see later).
The ubiquitin is transferred from the e1-ligase to the e2-ligase (Fig. 1 ). There are approximately 20 e2-ligases encoded by the human genome, in contrast to only 1 e1-ligase. Some e2-ligases are used for one ubiquitin family member-for example, Ubc9 is an e2-ligase unique to sumoylation (Johnson and Blobel 1997) . Different e2-ligases have specificity for different steps of the ubiquitination process; UbcH5a catalyzes the nonspecific lysine linkage of ubiquitin, whereas Ubc13 forms only Lys63-linked polyubiquitin chains (Windheim and others 2008) . In another recent report, the rapid monoubiquitination of cell cycle regulatory proteins by the aPC was identified as being mediated by Ubc4, whereas Lys48 polyubiquitination by the aPC was mediated by Ubc1 (Rodrigo-Brenni and Morgan 2007) . Interestingly, the e2-ligases interact with different domains on the e3-ligase (Windheim and others 2008) . The choice of e2-ligase may determine the topology of the substrate ubiquitination modification, and polyubiquitination of a target may require multiple e2/e3-ligase combinations.
In the final step of the process, the ubiquitin is transferred from the e2-ligase to the substrate by an e3-ligase. This reaction defines the target specificity of ubiquitination. There are two major e3-ligase families: the RINg (really interesting new gene) and HeCT (Homologous to the e6-aP Carboxyl Terminus) families. additional e3-ligases recently have been identified, including a novel zinc finger protein containing e3-ligase and a U-box domain containing proteins (Jiang and others 2001; Wertz and others 2004) . However, U-box proteins may be involved with polyubiquitin chain extension/ e4-ligase activity (see below). Furthermore, e3-ligase independent monoubiquitination has been reported; however, the significance of this observation is not yet clear (Hoeller and others 2007 Ubiquitin is synthesized as a precursor protein, whose C-terminus is cleaved by a deubiquitinating enzyme to reveal a C-terminus glycine residue. Seven lysine residues are present in the primary amino acid structure of ubiquitin, which allows multiple potential polyubiquitin chain linkages. (Lower) Ubiquitin is added to a substrate protein by the sequential action of an E1-ligase, E2-ligase, and E3-ligase. The different polyubiquitin chains have different topologies, which are associated with their function. Ubiquitin chains with a Lys48 linkage usually result in proteasomal degradation of the protein. Lys63-linked chains can target proteins to the proteasome or lysosome or play a role in protein-protein interactions.
the e3-ligase, to enable the access of the ubiquitin for transfer. In contrast, the HeCT e3-ligases form an intermediate e3-ligase-ubiquitin complex prior to the transfer of the ubiquitin to the target protein.
Whether all e3-ligases monoubiquitinate or polyubiquitinate target proteins is not yet clear. a fourth enzyme class, the e4-ligase, was recently described and shown to regulate polyubiquitin chain extension. Polyubiquitin chains in excess of four ubiquitin residues are required for proteasomal degradation of proteins (Thrower and others 2000) . Ubiquitin fusion degradation protein 2 (UFD2) functions with e1-, e2-, and e3-ligases to ubiquitinate a UFD substrate (UFD4). Omitting UFD2 from the reaction resulted in termination of the polyubiquitin chain with only three ubiquitins (Koegl and others 1999) . In addition, the first three ubiquitins were added via Lys29 linkages, whereas chain extension was with Lys48-mediated linkages (as shown by incubation with K29R and K48R ubiquitin mutants, respectively; Koegl and others 1999) . This study also showed that the e4-ligase contains a polyubiquitin binding domain, although it is not clear whether the binding of the e4 changes the conformation of the already attached ubiquitin. The authors suggest that e4-ligases may promote the degradation of posttranslationally activated protein by extending the oligoubiquitin chain (Koegl and others 1999) .
UFD2 contains a U-box domain, which may identify potential new e4-ligase members. an interesting member of this family is the e4-ligase CHIP (C-terminus of Hsc70-interacting protein), which functions with the e3-ligase mutated in a familial form of Parkinson disease, PaRKIN, to regulate Pael receptor degradation (Hoppe 2005; Imai and others 2002) . However, other studies suggest that CHIP also acts as an e3-ligase (Windheim and others 2008) . Whether all proteins that contain a U-box are e4-ligases remains to be determined, but e4-ligase activity has been reported in proteins that do not contain a U-box domain (Hoppe 2005) . The nuclear protein P300 recognizes MDM2 (Murine double minute 2)-mediated monoubiquitination of p53, promoting further ubiquitin chain extension (grossman and others 2003). P300 does not contain a U-box domain in its sequence, suggesting that another domain on this protein may function as the e4-ligase or the P300 recruits another e4-ligase. The target specificity of e4-ligases is not yet clear on whether this function is mediated by e2/e3-ligase combinations (Windheim and others 2008) . The elucidation of proteins with e3-and e4-ligase activity for specific proteins may reveal additional targets for drug manipulation of this system.
One of the more perplexing questions currently being investigated by a number of groups is the mechanism(s) by which the ubiquitin chain on a protein substrate is extended. a number of complex models have been proposed (Fig. 2) , and yet a clear answer is not apparent (see review by Hochstrasser 2006) . Following the addition of one or more ubiquitins to the substrate protein, the e3-ligase, which interacts with the substrate protein, will be too far from the end of the chain to mediate the conjugation of the next ubiquitin molecule. a number of models have been proposed to explain this issue. One suggested mechanism is that the polyubiquitin chains are synthesized prior to addition to the substrate, either by the e2-or e3-ligase. For example, Ube2g2/gp78-mediated polyubiquitination involves the assembly of polyubiquitin chains on the e2-ligase, prior to transfer to the substrate (Li and others 2007) . This may be why a number of studies have reported autoubiquitination of e2-and e3-ligases. alternatively, the initial e3-ligase monoubiquitinates the substrate; then, either different e2-ligases regulate chain extension, or an additional factor (the e4-ligase) regulates extension (Hoppe 2005) . Currently, different e3-ligases are being studied in different systems and under different physiological conditions, which may account for the unclear picture from these recent studies. Figure 2 . Potential models of polyubiquitination. Sequential addition of ubiquitin refers to the process of ubiquitin transferring from the E1-to the E2-and then to the E3-ligase onto the substrate; this process would then be repeated for each additional ubiquitin added to the chain. However, this model fails to describe how the E3-ligase, which interacts with the substrate protein, can physically reach the end of the ubiquitin chain. Some protein ubiquitination is mediated by multiple E3-ligases acting with the E3-ligase. The first E2-ligase mediates monoubiquitination, and the second E2-ligase promotes polyubiquitination. Some E2-ligases can assist in the transfer of presynthesized polyubiquitin onto the substrate. Finally, some proteins have E4-ligase activity. When added to the reaction, E4-ligases promote polyubiquitin chain extension.
Ubiquitin chains can be remodeled to change the function of the ubiquitin modification to regulate degradation (see Fig. 3 ). Wertz and others (2004) showed how, following tumor necrosis factor (TNF) receptor activation, the signaling protein receptor interacting protein (RIP-1) is bound to the TNF receptor complex via a Lys63-linked polyubiquitin modification. To turn down TNF receptor signaling, RIP-1 is deubiquitinated by the cofactor a20 (via its ovarian tumor domain [a DUB family domain]). Following deubiquitination, RIP-1 is Lys48 polyubiquitinated by a20, targeting it for proteasomal degradation and thereby turning off TNF receptor signaling. Interestingly, a20 contains a novel e3-ligase domain. The a20 zinc finger domain is structurally divergent from the RINg zinc finger domain common to many e3-ligases (Wertz and others 2004).
In addition to modification of the polyubiquitin chain prior to proteasomal trafficking, proteins at the proteasome are also subject to chain editing (Fig. 3) . The S26 proteasome contains multiple e3-ligases and DUB domains. Recent studies of the interplay between the ligase Hu15 and the DUB Ubp6 show that these enzymes can regulate substrate degradation by extending their ubiquitin chains and enhancing proteasome activity or by removing their ubiquitin modifications to reduce degradation (Crosas and others 2006) .
Taken together, these studies show that the process of protein ubiquitination is a tightly regulated process. The degradation of proteins by the ubiquitin proteasome system and subsequent loss of function determines the consequence for the cell (i.e., degradation of cell death proteins promotes protective phenotypes; Meller and others 2006) . However, ubiquitin has multiple functions, not just protein degradation. Consistent with a role in polyubiquitin chains mediating protein-protein interactions, a family of ubiquitin-like modifier proteins has been identified.
Ubiquitin Binding Domains, Protein Interactions by Ubiquitination
The binding of ubiquitin chains, which are associated with nonproteasome targeting, is accomplished by ubiquitin binding domains (UBDs) on the acceptor proteins. There are a number (>30) of different ubiquitin binding domain motifs that can bind to monoand polyubiquitin. Interestingly, the affinity of a UBD and ubiquitin is low, typically in the low micromolar range (Ikeda and Dikic 2008) . Because ubiquitin levels in cells are relatively high, this suggests that the regulation of binding is due to accumulation of UBD containing proteins in cellular compartments and the use of multiple UBDs within a protein/complex (Ikeda and Dikic 2008) .
Further analysis of this issue is ongoing, and it was recently shown that the 3D topology of Lys63-and Lys48-linked polyubiquitin may offer some ideas as to how the binding domains specific to each are accomplished. X-ray crystallography of Lys48-linked diubiquitin show a compact arrangement of the ubiquitin moieties; in contrast, Lys63 ubiquitin is more open and linear in shape others 2002, 2004) . Therefore, the structure of the Lys48 and Lys63 linkages is quite different. In a recent study of the binding affinities of different UBDs, four classes were described: those that bound monoubiquitin, linkage-selective and nonselective domains, and one class that did not bind any ubiquitin ligand (Raasi and others 2005) . Interestingly, the protein homologs containing UBDs show a remarkable conservation of ubiquitin chain specificity between species (Raasi and others 2005).
Ubiquitin-Like Modifiers
Ubiquitin is a member of an ever growing family of ubiquitin-like modifiers, which include SUMO, NeDD8, and atg. For more detailed information on these proteins, the reader is referred to some recent reviews (geiss-Friedlander and Melchior 2007; Kerscher and others 2006). These proteins have a similar tertiary structure to ubiquitin but have a lower amino acid homology to ubiquitin. a . A20 mediates deubiquitination of Lys63-polyubiquitinated receptor interacting protein (RIP-1). A20 can also catalyze the Lys48 polyubiquitination of RIP-1. At the proteasome, the actions of deubiquitinating enzymes and E3-ligases can prevent a substrate from proteasome degradation or extend the polyubiquitin chain and therefore enhance degradation. similar series of sequential reactions regulate the modification of proteins by ubiquitin-like modifiers; for example, sumoylation requires an e1-, e2-, and e3-ligase-mediated reaction. Modification by ubiquitin-like modifiers results in the regulation of protein function and localization, rather than direct protein degradation. These additional protein modifiers also interact with the ubiquitin system to regulate protein function, as discussed below.
Monoubiquitination
Most research has focused on how polyubiquitination (Lys48) results in protein degradation by the proteasome. Monoubiquitination has also been shown to regulate a number of divergent cellular processes (Hicke 2001) . One of the more commonly studied functions of monoubiquitination is the regulation of gene expression. Monoubiquitination of histone H2a and H2B is an important event for the elongation step of transcription. In addition, monoubiquitination functions as a signaling molecule for the assembly of transcription enzymes and unraveling of chromatin (see Weake and Workman 2008 for a review of histone ubiquitination and gene expression).
Monoubiquitination can also affect protein function outside of the nucleus. One such example is the regulation of receptor endocytosis (Hicke 2001 ). Monoubiquitination of a receptor or ion channel promotes endocytosis and internalization. These proteins are either deubiquitinated and recycled or subject to lysosomal degradation. In addition, the tumor suppressor protein p53 is exported from the nucleus to the mitochondria when it is monoubiquitinated (Marchenko and others 2007) , whereas polyubiquitination results in its proteasomal degradation. p53 is then deubiquitinated by HaUSP at the mitochondria, which enables its interaction with Bcl-2 family members (Marchenko and others 2007) .
Crosstalk between Ubiquitination, Phosphorylation, and Other Ubiquitin-Like Modifiers
Recent studies suggest that posttranslational modifiers do not work alone but rather form a complex system of signaling crosstalk to regulate biological processes (Hunter 2007) . The ubiquitination of a substrate can be regulated by its phosphorylation-for example, the phosphorylation of Bim on Ser 65 by eRK1/2 enables its interaction with its e3-ligase, resulting in ubiquitination and proteasomal degradation (Ley and others 2003; Fig. 4 ). Interestingly, the ubiquitination of multiple Bcl-2 family proteins is regulated by the phosphorylation of critical residues (Breitschopf and others 2000a) . In addition, nitrosylation of Bcl-2 regulates its degradation by the proteasome (Chanvorachote and others 2006) . Some kinases are also regulated by ubiquitination, which can turn on or off a biological signal; for example, RIP-1 is regulated by a20, which controls IKKb function following TNF receptor signaling (Wertz and others 2004).
The crosstalk between ubiquitin and the ubiquitinlike modifier SUMO has been the focus of many studies. Under normoxic conditions, hypoxia-induced factor (HIF) 1 is hydroxylated, promoting its ubiquitination by the e3-ligase VHL (von-Hippel Lindau tumor factor), resulting in protein degradation. Hypoxia induces the sumoylation of HIF1α, which also enables its ubiquitination by VHL. Desumoylation of HIF1α results in stabilization of the protein by preventing its ubiquitination and promoting the expression of HIF1-regulated genes (Cheng and others 2007) . These data are in contrast to other reports that suggest that sumoylation promotes HIF1α gene expression (Bae and others 2004) and suggest that either sumoylation/desumoylation may be involved in HIF1 degradation, perhaps similar to a20-mediated regulation of RIP-1, or additional signaling mediators may regulate HIF1α in response to hypoxia.
The tumor suppressor p53 is subject to complex regulation as signaling crosstalk, including phosphorylation, acetylation, nitrosylation, sumoylation, monoubiquitination, and polyubiquitination (Lavin and gueven 2006) . The stability of the e3-ligase that regulates p53 ubiquitination MDM2 is regulated by the tumor suppressor p14aRF and other regulatory proteins (Zhang and others 1998) . In addition, arf can regulate protein sumoylation (gallagher and others 2006). Hence, one can determine that ubiquitination (and other ubiquitin-like modifications of proteins) does not happen in isolation but rather as part of a highly complex, intricately regulated signaling system. given the specificity within the system and the remarkable variety of target proteins whose function and stability are regulated by the ubiquitin proteasome system, it is clear that further study of this system may reveal targets for therapeutic manipulation.
The Proteasome
To be targeted to the proteasome, a protein requires a polyubiquitin tail of at least four residues, resulting in a high affinity for the proteasome and subsequent processing. The proteasome complex allows the rapid complete and selective degradation of substrates due to its structure. The physical tube-like structure of the proteasome ensures that only targeted proteins are processed. The core is narrow, which requires the unfolding of a protein into a linear peptide sequence (Pickart and Cohen 2004) . The importance of the proteasome is underlined by the fact that many knockouts of proteasome subunits result in lethal phenotypes (Heinemeyer and others 1991; Orlowski 1999) . The S26 proteasome is made up of an S20 core and an S19 cap (the S denotes sedimentary coefficient; the molecular weights of the core and cap structures are approximately 760 and 1 Mda, respectively). The proteasome is structurally similar to the HsIV and CIsP proteases found in prokaryotic cells, but on an evolutionary basis, these proteases are unrelated. The S20 proteasome shows little protease activity on its own and requires the S19 cap proteins for full function (Pickart and Cohen 2004) . The catalytic core of the proteasome is formed by four 7-membered rings of α and b subunits (Baumeister and others 1998) . The catalytic sites are on the b subunits, whereas the α subunits control the passage of substrates to the catalytic sites.
The proteasome S19 cap is made up of approximately 17 subunits (designated RPN in Caenorhabditis elegans or yeast). The cap is the site of protein unfolding, a process that requires aTP. Indeed, many of the cap subunits possess aTPase activity. The cap forms a ring and a lid-type feature to regulate entry of the protein to the protease (Baumeister and others 1998; Pickart and Cohen 2004) . as well as unfolding the protein, the cap is the site for removal of the ubiquitin chain prior to degradation of the protein, allowing ubiquitin to be recycled by the cell. Two types of deubiquitinating enzymes act on substrates: USP14 removes the proximal ubiquitin from a protein, whereas UCH (ubiquitin C-terminal hydrolases) removes distal ubiquitins from the substrate. Recently, it was shown that the cap also contains e3-ligase activity. The role of this is not clear, but the e3-ligase Hu15 functions with the deubiquitinating enzyme USP14 to regulate protein degradation (Crosas and others 2006) .
The Role of the Ubiquitin-Proteasome System in Ischemia and Ischemic Tolerance
The ubiquitin proteasome system has been implicated in a number of pathologies that effect neuronal structure and function. Proteasome inhibitors, when administered for long durations or at high concentrations, induce neuronal cell death (Qiu and others 2000) . Blocking proteasome function delays axonal degeneration following cell injury or axon cutting (Wallerian degeneration; Zhai and others 2003) . Interestingly, the wld s mutant mouse shows a slowing of the degeneration and expresses a mutant form of the UFD2 e4-ligase lacking catalytic activity fused to nicotinamide mononucleotide transferase (Mack and others 2001).
Ubiquitin-rich inclusions are a common feature of certain neurodegenerative diseases, such as alzheimer disease and Parkinson disease. These plaques tend to be enriched in ubiquitin, and it has been suggested that they are deposits of misfolded proteins. accumulation of the proteins into aggregates may overwhelm the proteasome system, resulting in cell stress and neuronal death. For more details on the role of the ubiquitin proteasome system in these diseases, the reader is referred to the following reviews (Lim 2007; Oddo 2008) .
a number of studies have investigated protein ubiquitination and proteasome activity following ischemia ( Fig. 5 ). These studies suggest detrimental effects of the ubiquitin proteasome system following ischemia, resulting in damage to cell components or mediating inflammatory responses and leukocyte infiltration to the brain. Ischemia in the brain is modeled by either a local reduction in blood flow to a discrete brain area (focal ischemia) or a complete reduction in blood flow to the entire brain (global ischemia) (Traystman 2003) . Following global ischemia, the ubiquitination of proteins that form aggregates has been reported (Liu and others 2005b) . These protein aggregates contain polyribosomes, translation-associated proteins, and the e3/ e4-ligase CHIP (Liu and others 2005b) . Following global ischemia, the prolonged accumulation of polyubiquitinated proteins in the postsynaptic density has been reported in the selectively vulnerable hippocampal regions but was briefly found in the ischemiaresilient dentate gyrus cells others 2004, 2005b) . However, these studies did not identify which type of polyubiquitin linkage was added to the proteins.
The proteasome is also affected by harmful ischemia, resulting in cap disassembly and the trafficking of these cap subunits to protein aggregates and a reduction in proteasome function. The formation of aggregates by ubiquitinated proteins, due to impaired proteasome function, may contribute to cell stress following ischemia, thereby amplifying the neuronal damage to the neurons.
Preconditioning neurons with brief ischemia resulted in a reduction in protein aggregation following ischemia (Liu and others 2005a) . Both the formation of triton-X100 insoluble ubiquitinated proteins and the depletion of free ubiquitin following harmful ischemia were reversed in ischemic-tolerant (delayed) neurons. However, it is not clear whether the proteins are less ubiquitinated because tolerant cells are not damaged by the ischemia or whether the tolerance reduces protein aggregation, thereby protecting the cells. Interestingly, ischemic tolerance is associated with raised heat shock protein expression, and raised heat shock protein levels result in less ubiquitin redistribution in neurons following ischemia (Ouyang and others 2005) . a number of protein substrates have been identified as being regulated by the proteasome following ischemia. Ubiquitination of survival proteins following ischemia has been reported in the retina. analysis of a gracile axonal dystrophy mouse reveals an exon deletion of ubiquitin C-terminal hydrolase-L1. These mice show less ubiquitination of Bcl-2 and XIaP in response to ischemia compared to wild-type mice (Harada and others 2004) . In addition, PKC γ, type 2 iodinase, and aKaP121 are degraded by the proteasome following ischemia (Carlucci and others 2008; Lamirand and others 2007; Matsumoto and others 2004) . Hence, a number of proteins are subject to ubiquitination following ischemia, which may regulate cell fate.
Ubiquitination may regulate autophagic processing of proteins following ischemia as well as proteasomal protein degradation. autophagy is a lysosomal-dependent mechanism of degrading proteins and organelles. autophagosomes form by enveloping the cytosol by a phagophore (a membrane sac) in a highly regulated process, which then fuses with a lysosome containing proteases that degrade the contents. autophagy has divergent effects, which are relevant to ischemia and other neuropathological conditions. autophagic neuronal death has been reported in response to ischemia (adhami and others 2006; Carloni and others 2008; Koike and others 2008; Qin and others 2008; Uchiyama and others 2008). However, whether autophagy is a survival or damaging response is not yet clear. although autophagic cell death has been reported since the 1960s and is a mechanism of cell death, which can proceed without the apparent biochemical hallmarks of programmed cell death (i.e., caspase cleavage and activation), some studies suggest a protective role (Carloni and others 2008) . Hence, the activation of autophagic processes following ischemia/neuronal damage could be a double-edged sword (for a review on ischemia and autophagy, see Rami and Kogel 2008) . Therefore, it is not yet clear whether the autophagic clearance of ubiquitinated proteins is a reserve for the proteasome or a separate system for protein clearance, which is activated in response to an overwhelming of the proteasome following ischemia.
Proteasome Inhibitors Reduce Ischemia-Induced Brain Injury
Further evidence implicating a role of the ubiquitin proteasome system in ischemia-induced cell damage comes from studies showing that proteasome inhibitors reduce brain infarction following ischemia in animal models. There are two classes of proteasome inhibitors. The first class, such as clasto-lactacystin-b-lactone (usually administered as a pro-drug lactacystin), is derived from naturally occurring compounds from bacteria/fungi. The second class of inhibitors includes Proteasome overload
Brief ischemia reperfusion
Cell death Neuroprotection (Rapid ischemic tolerance) Figure 5 . Overview of potential role of ubiquitin proteasome system in mediating the cellular response to ischemia. Brief ischemia can result in the rapid degradation of proteins by the proteasome and tolerance to ischemia. In contrast, following harmful ischemia, the accumulation of ubiquitinated proteins may contribute to cell stress. Harmful ischemia reduces proteasome function. The ubiquitinated proteins form aggregates that are subject to autophagic processing. Whether autophagy is a protective response or promotes further cell stress following ischemia is unclear.
short, modified peptides, such as the classical proteasome inhibitor Mg132 (carbobenzoxy-L-leucyl-L-leucyl-L-leucinal) and bortezomib. It is noteworthy that some of these inhibitors can block other proteases such as caspases, calpains, and cathepsin. For structures and pharmacology of proteasome inhibitors, the reader is referred to the review by Wojcik and Di Napoli (2004) . The proteasome inhibitor MLN519, which is structurally similar to lactacystin (Wojcik 1999 ), provides effective neuroprotection in models of focal ischemia (2 hours middle cerebral artery occlusion) when given up to 4 hours postischemia (Williams and others 2003). MLN519-treated rats show less neuronal damage, astrocytic damage, leukocyte infiltration, and infarction compared to untreated rats subjected to injurious ischemia. The dose of MLN519 reduced blood proteasome activity by 80% and also decreased NFκB activation. Protection was not evident in this study at 8 hours post ischemia (Williams and others 2003).
In follow-up studies, MLN519 shows neuroprotective effects in behavioral assessment when administered up to 10 to 48 hours following ischemia others 2004, 2005) . MLN519 increased survival and reduced ischemia-induced weight loss. In addition, animals subjected to ischemia and MLN519 also performed better in some neurological tests than ischemia-treated controls. This exciting study suggests that proteasome inhibitors may be a useful strategy to reduce delayed postischemic brain injury. Indeed, there is a similar temporal profile of postischemic brain injury and neuroinflammation (Dirnagl and others 1999) . This may be a more feasible therapeutic time point to investigate, given the failure of previous neuroprotective therapeutic strategies that targeted apical events following ischemia and hence had a narrow therapeutic time window (N-methyl-D-aspartate [NMDa] receptor antagonists and calcium channel blockers).
Bortezomib (Velcade), a dipeptide boronate derivative approved for multiple myeloma, also reduces ischemia-induced brain injury. In a study of embolic focal ischemia, bortezomib induced protection up to 4 hours after ischemia and also enhanced the therapeutic time window for tissue plasminogen activator therapy to 6 hours (Zhang and others 2006b) . In a separate study, bortezomib reduced brain injury in a permanent middle cerebral artery occlusion model and a second embolitic model (Henninger and others 2006) . These studies show that bortezomib reduces blood proteasome activity by 77% and also reduces NFκB and eNOS (nitric oxide synthase) expression following harmful ischemia (Henninger and others 2006) .
These studies suggest that as a poststroke therapy, proteasome inhibitors may have therapeutic efficacy in reducing neuroinflammation-associated delayed cell death in the brain. This view is supported by the fact that proteasome inhibitors do not protect neurons from in vitro modeled ischemia or glutamate toxicity (Meller and others 2008; Waataja and others 2008) . The global blockade of the proteasome, however, may result in many unwanted side effects, and as such, the future target for this research will be to identify critical molecular mechanisms that are blocked by the proteasome inhibitors to develop more specific therapeutics. In addition, the proteasome may also mediate protective events, which may be promoted to induce protection against ischemia. This mechanism is slowly being revealed by the study of the endogenous protective phenomenon of ischemic tolerance.
Protein Ubiquitination and Ischemic Tolerance
Tolerance, induced by a preconditioning event, is a universal phenomenon and has been observed in many species and organs. a preconditioning agent is defined as an agent or stimulus, which at a low dose is not toxic but induces protection against a larger toxic dose (tolerance; Dirnagl and others 2003; Janoff 1964) . The protection induced by preconditioning can render the organ/system protected from other harmful stimuli (cross-tolerance); for example, endotoxin (lipopolysaccharide [LPS]), seizures, and spreading depression all induce tolerance to ischemia (ahmed and others 2000; Kobayashi and others 1995; Rosenzweig and others 2007) . Many early studies of ischemic tolerance focused on the protection of the myocardium following the induction of ischemic tolerance, but ischemic tolerance was soon reported in the brain (Kitagawa and others 1990) . although many of the earlier heart studies have guided experiments in the brain, differences exist between the two systems (Tauskela and others 1999) .
Ischemic tolerance has been observed in murine, gerbil, and rat models of ischemia and following focal or global ischemia (Dirnagl and others 2003) . Ischemic tolerance has been modeled in vitro using oxygen glucose deprivation (OgD), hypoxia (low-oxygen) chemical ischemia with metabolic inhibitors, and glutamate/ NMDa agonists, suggesting that the ischemic tolerance phenomenon is not just a blood reperfusion effect (Chen and Simon 1997; Meller and others 2005) . However, the ability of preconditioning in one body region to induce ischemic tolerance in another (remote preconditioning) suggests that in the whole-body situation, a vascular preconditioning mediator is released, which can induce tolerance in a different tissue (Ren and others 2008) .
evidence from prospective and retrospective studies suggests a potential role of ischemic tolerance in humans (Schaller 2005 ; Schaller and graf 2002; Wegener and others 2004; Weih and others 1999) . Patients with prior transient ischemic attacks to the same territory of the brain affected by a subsequent stroke have a reduced infarct volume and severity of symptoms. Hence, endogenous ischemic tolerance in the human brain exists.
There are two accepted time windows for ischemic tolerance following the preconditioning stimuli. a rapid time window has been shown to exist 30 minutes to 1 hour following preconditioning. In contrast, delayed tolerance is induced 24 hours following preconditioning and can last up to 3 days. although intermediate time windows have been reported (Ren and others 2008) , the difference in time windows of the two types of tolerance gives clues as to the biological mechanism of each. Delayed tolerance is mediated via new protein synthesis and a change in the genomic response to ischemia. The protein synthesis inhibitor cycloheximide blocks delayed tolerance in both in vivo and in vitro models (Barone and others 1998; others 2005, 2006) . In contrast, cycloheximide did not block an in vitro rapid ischemic tolerance model in rat cortical neurons (Meller and others 2006) . Many studies of ischemic tolerance have focused on the gene-based, de novo protein synthesis-dependent long-term/delayed ischemic tolerance (for more detailed reviews, see Chen and Simon 1997; Dirnagl and others 2003; Obrenovitch 2008; Steiger and Hanggi 2007) .
Studies of the molecular mechanism of delayed ischemic tolerance have identified a number of important genes whose neuroprotective effects may mediate tolerance to harmful ischemia, including Bcl-2, Bcl-w, heat shock proteins, proliferating cell nuclear antigen, glutamate transport proteins eaaT2/3, and erythropoietin (Bossenmeyer-Pourie and Daval 1998; Currie and others 2000; McLaughlin and others 2003; Minami and others 2000; Ruscher and others 2002) . More recently, it has been proposed that a preconditioning event results in a reprogramming of the genomic response of the brain to subsequent harmful ischemia and has similarities to the natural protective state of hibernation (Stenzel-Poore and others 2003 , 2004 . gene-based and metabolic-based mechanisms of endogenous tolerance to ischemia are observed in a number of divergent species and scenarios, including mammal hibernation, deep sea turtles, arctic ground squirrels, fish, and beetle larvae (Frerichs and Hallenbeck 1998; Frerichs and others 1994; Hoback and others 2000; Lee and others 2007; Podrabsky and others 2007; Storey 2003 Storey , 2007 .
Rapid Ischemic Tolerance in Animal and Cell Culture Models of Ischemia
In contrast to delayed ischemic tolerance, rapid ischemic tolerance has been studied less extensively. Rapid ischemic tolerance has been described in the heart (eisen and others 2004) and also occurs in brain. However, less is known about the molecular mechanisms by which rapid ischemic tolerance induces its neuroprotective effects in brain compared to delayed tolerance. Indeed, approximately 20 studies have directly investigated the molecular mechanisms of rapid tolerance-induced neuroprotection.
The first report of rapid tolerance to ischemia in the brain was by Schurr and others in 1986. They showed that rat hippocampal slices exposed to anoxia 30 minutes prior to harmful ischemia (anoxia) maintained electrical responsiveness of the cells (Schurr and others 1986). Rapid ischemic tolerance has been observed in primary cortical neuronal cultures, organotypic preparations, or slices of hippocampus using anoxia, oxygen and glucose deprivation, NMDa, and pharmacological preconditioning stimuli (Bandyopadhyay and others 2002; Meller and others 2006; Perez-Pinzon and Born 1999; Reshef and others 1996; Schurr and others 1986) . Typically, most studies use a one-hour interval between preconditioning and harmful ischemia, although protection is also observed within a 30-minute window (Perez-Pinzon and others 1997). Rapid ischemic tolerance in vitro protects against oxygen glucose deprivation, chemical-induced ischemia (iodoacetate), anoxia, and NMDa excitotoxicity (Meller and others 2008; Reshef and others 1996) .
Rapid ischemic tolerance has also been described in animal models of ischemia. The protection one observes depends on the duration of reperfusion following the second, harmful ischemia and the severity of the second ischemic insult. For example, rapid ischemic tolerance, using 3 × 5-minute periods of middle cerebral artery (MCa) occlusion in mice, 30 minutes prior to 60-minute MCa occlusion (MCaO) or permanent MCaO, reduced infarction 24 hours following the final ischemic insult (Stagliano and others 1999) . In a global model of ischemia in rats, protection induced by 2 minutes of bilateral carotid occlusion followed by 30 minutes of reperfusion resulted in protection to a 10-minute occlusion when assessed three but not seven days later (Perez-Pinzon and others 1997). Other studies have reported rapid ischemic tolerance in focal models of ischemia (atochin and others 2003; Nakamura and others 2002). Preconditioning animals with a 30-minute MCaO resulted in protection from a 180-minute MCaO one hour later, and the protection was evident seven days following the last ischemic insult. We observed similar protection in a focal model of rapid ischemic tolerance when we paired a 30-minute MCaO with a 60-minute reperfusion followed by a 100-minute harmful MCaO (Minami and others 2003) .
The concept of remote preconditioning to induce ischemic tolerance has been investigated (Ren and others 2008) . The authors showed that three cycles of occlusion of the femoral artery (left) resulted in protection from ischemia induced by permanent occlusion of the left distal MCa combined with a 30-minute occlusion of the bilateral common carotid arteries. This suggests that rapid ischemic tolerance can be induced remotely, which has interesting clinical implications. Furthermore, this suggests that endogenous rapid ischemic tolerance in the whole animal is induced by the release of a mediator into the bloodstream, as well as occurring in the tissue. a number of mechanisms have been investigated with respect to rapid ischemic tolerance. Many studies have described a role of adenosine receptors in mediating tolerance induced by anoxia, isoflurane, and adenosine receptor agonists (Liu and others 2006; Perez-Pinzon and others 1996; Reshef and others 1996) . In addition, in vitro and in vivo rapid ischemic tolerance is blocked by the adenosine a1 receptor antagonists 8-Cyclopentyl-1,3-dipropylxanthine (DCPCX) (Nakamura and others 2002; Perez-Pinzon and others 1996) . The source of the adenosine that is mediating these effects following the brief ischemic event is not yet clear, and potential mechanisms could include excytotoxic release of adenosine, transporter-mediated release, or metabolism of aTP into adenosine (Parkinson and others 2002). Other neurotransmitter receptors that may regulate rapid ischemic tolerance include the delta opioid receptor. Rapid ischemic tolerance to glutamate excitoitoxicity following hypoxic preconditioning is blocked by the delta opioid receptor antagonist naltrindole (Zhang and others 2006a) . The mechanisms that regulate delta opioid-induced tolerance are not yet clear.
Rapid ischemic tolerance induced by preconditioning with anoxia and the metabolic poison iodoacetate can be blocked by the inhibitor of the aTP-sensitive potassium (K aTP ) channel glibenclamide. The effect of adenosine in mediating protection against iodoacetate is also blocked by glibenclamide. a rapid tolerant state in neurons can be induced by incubation for 30 to 60 minutes with the K aTP channel openers chromakalin, diazoxide, and pinacidil (Perez-Pinzon and Born 1999; Reshef and others 1998). Taken together, these data suggest that the activation of K aTP channels following preconditioning via the increased adenosine a1 receptor activation plays a role in rapid ischemic tolerance.
The Ubiquitin Proteasome System and Rapid Ischemic Tolerance
The most obvious difference between delayed and rapid ischemic tolerance is the time window for effect. as the name implies, rapid ischemic tolerance occurs quickly following the preconditioning stimuli and is not blocked by the protein synthesis inhibitor cycloheximide (1 µM; Meller and others 2006) . This suggests that the neuroprotective mechanism of rapid tolerance occurs independently of new protein synthesis. Therefore, the protective mechanism of rapid ischemic tolerance would be predicted to result in the rapid posttranslational modification of in situ proteins to mediate the neuroprotective event.
Consistent with this hypothesis, the potential role for the ubiquitin proteasome system in regulating rapid ischemic tolerance both in brain and in heart was recently described (Cai and others 2008; others 2006, 2008) . Rapid ischemic tolerance is blocked by multiple proteasome inhibitors (clasto-lactacystin b-lactone, Mg132 [Z-Leu-Leu-Leu-CHO] and Mg115 [Z-Leu-Leu-Nva-H]), suggesting that following preconditioning ischemia, proteins are degraded, resulting in a neuroprotective phenotype others 2006, 2008) . This concept of down-regulation or depletion of proteins to generate a protective phenotype has been suggested by others; gene transcriptional down-regulation is a common phenotype of delayed ischemic tolerance (Stenzel-Poore and others 2003). In addition, ischemic tolerance in a cardiac protection model was recently shown to be blocked in a transgenic mouse deficient for low molecular mass polypeptide 2 (LMP-2; a subunit of the immunoproteasome). This mechanism of protection was attributed to activation of aKT, due to degradation of the repressor PTeN (phosphatase and tensin homologue deleted on chromosome 10; Cai and others 2008).
Ubiquitination of the Pro-Cell Death Protein Bim following Preconditioning Ischemia
The first protein shown to be ubiquitinated in a model of rapid ischemic tolerance was the pro-cell death member of the Bcl-2 protein family, Bim. The balance between prosurvival and proapoptotic Bcl-2 family proteins regulates the initiation of intrinsic cell death signaling upstream of the mitochondria. Multiple Bcl-2 family proteins are regulated by the ubiquitin-proteasome system (Basu and Haldar 2002; others 2000a, 2000b; Li and Dou 2000) . Bim, a procell death member of the Bcl-2 family, is a member of the BH3-only subgroup of proteins (O'Connor and others 1998). Bim is commonly expressed as Bim eL (a 23to 26-kDa protein), but splice variants result in a truncated Bim L or Bim S , which are also potent cell death inducers (O'Connor and others 1998) . additional splice variants have been identified in humans, but their function is not yet clear (Miyashita and others 2001) . Bim can induce apoptosis via the direct activation of Bax/ Bak, whereas other BH3-only-containing Bcl-2 proteins result in sensitization alone (Kuwana and others 2005) . Bim induction has been shown to be essential for neuronal cell death (Putcha and others 2001), whereas reducing Bim protein levels reduces cell death in neurons (Strasser and others 2000) and renders them resilient to harmful ischemia (Meller and others 2006) .
Our studies show that only Bim, but not Bax or Bid protein, levels are rapidly decreased following preconditioning ischemia, and this decrease is associated with an increase in ubiquitination of Bim (Meller and others 2006) . The effect on Bim is transient; ischemic tolerance is lost four hours following preconditioning coincident with Bim levels returning to normal (Meller and others 2006) . The decrease in Bim is blocked by the proteasome inhibitor Mg132, which is consistent with preconditioning ischemia inducing Bim ubiquitination and proteasomal degradation that renders neurons protected against the harmful effects of ischemia.
Previous studies in mouse embryonic fibroblast (MeF) cells show that Bim ubiquitination is dependent on its phosphorylation of a Ser 65 residue by p42/p44 MaPK others 2003, 2005) . Furthermore, blocking p42/p44 MaPK activation blocks ischemic tolerance (Meller and others 2006) . Consistent with Bim ubiquitination playing a role in ischemic tolerance, blocking p42/p44 MaPK also prevents Bim ubiquitination and degradation (Fig. 4) . given the promiscuous nature of p42/p44 MaPK, it is reasonable to assume that this is not the only target for MaPKmediated phosphorylation following preconditioning ischemia.
What has yet to be identified is the e3-ligase responsible for ubiquitinating phosphorylated Bim following preconditioning ischemia. It has been suggested that the tyrosine kinase c-Cbl is a Bim e3-ligase in osteoclasts (akiyama and others 2003). However, other studies have failed to show an increase in Bim protein levels in the testes of c-Cbl knockout mice, which would be expected if the e3-ligase is absent (el Chami and others 2005) . Further evidence against a role of c-Cbl comes from studies that show that the biology of the interaction between c-Cbl and Bim does not match the known biology of Bim ubiquitination (Wiggins and others 2007) . For example, Bim ubiquitination is not affected by mutation of tyrosine residues on Bim, whereas mutation of serine residues (Ser 69) prevents Bim ubiquitination. Bim fails to interact with c-Cbl under conditions in which Bim ubiquitination increased, Bim stability is not affected by knockout of c-Cbl in MeF cells, and finally p42/p44 MaPK-mediated Bim ubiquitination occurs in fibroblasts obtained from c-Cbl knockout mice. Recently, the e3-ligase CIS has been suggested as a Bim e3-ligase. Zhang and others (2008) show how CIS is associated with the microtubule scaffold in cells and that microtubule depolymerizing agents release Bim and enable its association with CIS, resulting in its ubiquitination. However, the authors did not investigate the regulation of this system by p42/p44 MaPK. This leads to an intriguing situation: What else is ubiquitinated following preconditioning ischemia? Is Bim ubiquitinated by multiple e3-ligases? and do different e3-ligases interact with Bim under different biological conditions?
Proteomic Analysis of Ubiquitinated Proteins in Rapid Ischemic Tolerance
We recently employed a nonbiased proteomic approach to screen for ubiquitinated proteins in rapid ischemic tolerance (Meller and others 2008) . The agarose-bound UBD of p62 was used to enrich ubiquitinated proteins from preconditioned tissue, which were subsequently identified by mass spectrometry. Our results show a higher pulldown/identification of proteins following preconditioning ischemia compared to control. Some proteins were identified in both control and preconditioned tissue, but unfortunately, the absolute levels could not be determined. It was not determined whether these proteins are regulated by the same or different e3-ligases. Whether these proteins are Lys63 or Lys48 linked is not clear. However, further analysis showed that the degradation of two candidate proteins (myristoylated, alanine-rich C-kinase substrate [MaRCKS] and fascin) was inhibited by the proteasome inhibitor Mg132. These data would suggest that the ubiquitination of these proteins resulted in their proteasomal degradation.
Bioinformatic analysis of the proteins identified by our proteomic approach revealed an interesting function of the identified proteins: 16 of 25 proteins had been identified to interact either directly or indirectly with proteins associated with the postsynaptic density. This strongly suggests that the ubiquitin proteasome could be changing synaptic function, which may be associated with protection.
actin is a major cytoskeletal component of the postsynaptic density, so we focused our investigations on two actin binding proteins, fascin and MaRCKS (Meller and others 2008) . To maintain the shape and function of the spine, actin forms filaments that are cross-linked by other proteins to provide strength, and one such protein is fascin. Fascin regulates the shape and trajectory of neurites in Drosophila neurons (Kraft and others 2006) . actin does not directly anchor to the plasma membrane but contacts intermediate proteins such as MaRCKS (Hartwig and others 1992; Sundaram and others 2004) . Interestingly, NMDa induces degradation of MaRCKS but via the proteases cathepsin and calpain rather than the proteasome (graber and others 2004). Following preconditioning ischemia, proteasome-mediated degradation of MaRCKS and fascin occurs, resulting in a decrease in the interaction of these proteins with actin (Meller and others 2008) .
In our study, we show the proteasome-dependent degradation of two actin binding proteins following preconditioning ischemia, which is associated with the solublization of actin filaments and the loss of dendritic spines. The loss of spines was blocked by jasplakinolide and the proteasome inhibitor Mg132, suggesting that the ubiquitination of proteins and actin depolymerization following preconditioning results in structural reorganization of the neuron (Meller and others 2008) . Because ischemic tolerance-induced protection was also blocked by jasplakinolide and Mg132, this suggests that these structural changes are critical for rapid ischemic tolerance (Meller and others 2008) .
The concept that ischemia can remodel the synapse is not new. Indeed, in a series of studies, Mark goldberg's group showed that brief ischemia results in dendritic spine loss, whereas longer ischemia results in permanent spine loss (Faddis and others 1997; others 2001a, 2001b) . Dendritic spine loss following ischemia has also been reported following focal ischemia in vivo (Zhang and others 2005) . Dendritic spine loss is recoverable if the exposure to ischemia is transient and nonharmful but is persistent when toxic levels of ischemia occur (Park and others 1996; Zhang and others 2005) . Spine numbers recover approximately two to four hours following ischemia (Meller and others 2008; Park and others 1996) . Interestingly, the recovery of the spines occurs at the same location on the dendrite that the spines were originally lost, both in vitro (Hasbani and others 2001a) and in vivo (Zhang and others 2005) , suggesting a postsynaptic remodeling event.
The ubiquitin proteasome system also has been implicated in synaptic reorganization in response to neuronal activity and in LTP (Dong and others 2008; ehlers 2003; Fonseca and others 2006) . The dendritic spine is the major site of postsynaptic input to a neuron. The postsynaptic density, a region of dense cellular material adjacent to the synapse, is rich in proteasome subunits and ubiquitin (Chapman and others 1992). The development of synapses in a number of species is regulated by the ubiquitin proteasome system (Yi and ehlers 2007) . In addition, proteasome inhibitors can induce neurite outgrowth in PC12 cells treated with nerve growth factor (NgF; Maufroid and others 1996), but inhibition of N-end ubiquitination results in reduced neurite outgrowth (Obin and others 1999) .
When neurons are activated, proteasome subunits enter the dendritic spine and associate with the actin cytoskeleton (Bingol and Schuman 2006) . Hence, the proteasome is positioned to regulate (degrade) cytoskeleton proteins as reported following both ischemia and neuronal activation (ehlers 2003; Meller and others 2008) . activation of neurons resulted in remodeling of the synapse by the enhanced and decreased degradation of postsynaptic-associated proteins. The proteins regulated included neurotransmitter receptors and structural proteins (ehlers 2003). These structural changes resulted in long-lasting enhancement of NMDa-mediated CReB signaling. Phosphorylation of the transcription factor CReB is associated with protection and survival in neurons following ischemia (Walton and others 1999) .
Stimulation of neurons can also change the receptor composition of the postsynaptic density. PSD-95 levels decrease, reducing aMPa receptor subunit levels at the membrane surface and endocytosis of gluR1 subunits (Bingol and Schuman 2004; Colledge and others 2003) . Further studies show that PSD-95 is ubiquitinated by MDM2 (which is normally associated with p53 regulation; Colledge and others 2003) . In contrast, activation of a neuron reduces gaBa receptor ubiquitination, enhancing their numbers at the membrane surface (Saliba and others 2007;  in unpublished studies, we have observed enhanced gaBa currents following preconditioning ischemia). Interestingly, it has recently been shown that nicotine can inhibit proteasome function, resulting in the accumulation of ubiquitinated proteins (Rezvani and others 2007) . Nicotine has a direct binding ability with the proteasome, which may have many implications given the high social use of this drug.
These studies would suggest that, perhaps not surprisingly, one of the major consequences of ischemia-induced protein ubiquitination and degradation is a change in synaptic function (Fig. 6 ). Our studies have confirmed this hypothesis, in that we observe a reduction in NMDa currents and toxic NMDa signaling following preconditioning in a rapid ischemic tolerance model (Meller and others 2008) . The reduction in NMDa excitotoxicity following preconditioning was blocked by jasplakinolide and Mg132, which suggests that the same mechanisms that regulate tolerance to ischemia also result in tolerance to toxic levels of NMDa. a loss of synaptic NMDa receptors has been shown to result in tolerance to OgD (Sattler and others 2000) , and disrupting postsynaptic NMDa receptor-PSD-95 interactions also results in reduced toxicity following ischemia (Sattler and others 1999) . Waataja and others (2008) recently reported a study that correlates with our own observations, in that NMDa receptor activation resulted in PSD-95 degradation by the proteasome and a loss in dendritic spines. These changes were blocked by the proteasome inhibitor Mg132 and overexpression of p14aRF (which regulates MDM2 stability). Furthermore, a loss of spines following NMDa exposure resulted in a loss of excitatory postsynaptic potentials (ePSPs), which suggests that synaptic NMDa receptors were blocked or absent (Waataja and others 2008) . glutamate toxicity in these cells was not mediated by the proteasome, similar to OgD-mediated cell death in our experiments (Meller and others 2008) . However, toxicity to glutamate was enhanced in aRF overexpressing cells (Waataja and others 2008) . Furthermore, the glutamateinduced loss of spines was similar in time course to the ischemia-induced loss of spines, complete by one hour and recovering to control levels by three to four hours (Hasbani and others 2001a; Meller and others 2008) . The study by Waataja and others (2008) did not investigate whether the glutamate response or excitoxicity was reduced in cells pretreated with glutamate. Taken together, these two studies suggest that proteasome-dependent removal of dendritic spines occurs following a preconditioning ischemia and that this is a protective event.
Translating the Promise: Future Targets for Research
Following ischemia, the pattern of activation of intracellular mechanisms denotes the potential therapeutic time windows to a given strategy. Ischemia-induced cell death is a progressive event and requires 24 to 48 hours to fully develop (Dirnagl and others 1999; Fig. 7) . Studies on the role of the ubiquitin proteasome system in ischemia and rapid ischemic tolerance suggest two potential therapeutic strategies (Fig. 7) . Based on studies of rapid ischemic tolerance, acute neuroprotection may be an obtainable therapeutic goal. By further understanding the mechanism by which cell death-mediating proteins are rapidly degraded by the ubiquitin proteasome system, one could devise therapies to stimulate their degradation. Bim degradation is rapid, occurring one hour following preconditioning. given the established role of the Bcl-2 family of proteins in mediating cell death following ischemia and other brain injuries, a reduction in Bim may result in neuroprotection (Meller and others 2006; Shinoda and others 2004) .
a second phase of therapy would involve the reduction in secondary brain injury and neuroinflammation. These have been shown to be reduced by proteasome inhibitors. although acute therapy with these agents may be tolerated, proteasome inhibitors may aggravate part of the response to ischemia by inducing accumulation of ubiquitinated proteins that must then be cleared by autophagic processes. By further understanding the molecular mechanisms that regulate neuroinflammation, a more specific target therapy may be devised. Indeed, the ubiquitin proteasome system contains many elements, not only the e1-, e2-, and e3-ligases but also additional modifying factors, each of which is a potential target for molecular intervention. Furthermore, knowledge of the mechanisms that regulate these processes may be transferable to other neurological diseases of which cell death is a feature. This remains an exciting time for ubiquitin research, and therapies based on this versatile signaling system are no doubt being developed. . Potential therapeutic sites of intervention based on ubiquitin proteasome-mediated protection. Initial therapeutic strategies may target proteins whose rapid degradation is identified as being neuroprotective in rapid ischemic tolerance models. Delayed cell death has also been attributed to neuroinflammation processes following ischemia. Proteasome inhibitors have shown to provide delayed therapeutic effects in reducing infarction and behavioral deficits by reducing neuroinflammation. A combined therapeutic strategy targeting multiple processes that contribute to cell death following ischemia may effectively reduce brain injury following stroke. Time course figure adapted from Dirnagl and others (1999) . Figure 6 . Overview of preconditioning ischemia-mediated morphological reorganization in dendrite and alterations in N-methyl-Daspartate (NMDA) receptor-mediated signaling. Following preconditioning ischemia, protein degradation and actin reorganization result in uncoupling of the NMDAR (NMDA) receptor complexes from the actin cytoskeleton. The morphological and cytoskeleton changes result in an uncoupling of the toxic NMDA receptor-mediated signaling but not physiological NMDA receptor function. As a result, NMDAmediated excitotoxicity is reduced following preconditioning ischemia. This result may help identify how to switch off harmful NMDA receptor-mediated signaling.
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